Sorrento Therapeutics' Slow-But-Steady Approach to COVID-19

Brian Orelli, PhD, The Motley Fool
·4 min read

Ji thinks the company's neutralizing antibodies are potentially more active than the frontrunners, which could help the biotech catch up and compete. Brian Orelli: We talked about a lot of different products. Henry Ji: Brian, our company has a lot of expertise, especially the antibodies space.